62: A retrospective multicentre audit of outcome among patients with anaplastic lymphoma kinase (ALK) gene rearrangement positive non-small cell lung cancer (NSCLC) who have been treated with crizotinib in England
Titel:
62: A retrospective multicentre audit of outcome among patients with anaplastic lymphoma kinase (ALK) gene rearrangement positive non-small cell lung cancer (NSCLC) who have been treated with crizotinib in England
Auteur:
Yip, K. Conibear, J. Woolf, D. Tarver, K. Willis, B. Hall, S. Sun, F. Kuhan, H. Lambourne, B. Piskilidis, P. Kussaibati, R. Martin, L. Satar, N. Abdul Gray, C.M.N. Khan, A. Doherty, G. Prewett, S. Smith, M. Dancey, G. Patterson, D.M. Rimmer, Y. Hollingdale, A. Ingle, C. Tasigiannopoulos, Z. Aslam, S. Waite, K. Polychronis, A. Ghafoor, Q. Baijal, S. Newsom-Davis, T. Shah, R. Forster, M. Mulatero, C. Greystoke, A. Postmus, P.E. Blackhall, F. Gilligan, D.